ISB News

A clear, big-picture read that follows the discovery of the immune system’s “brakes” from early genetic clues to a Nobel-morning payoff – spotlighting Mary Brunkow’s role and how regulatory T cells reshaped care for autoimmune disease and beyond.

A photographer from The Associated Press was on Mary Brunkow’s front door in the early hours of October 6, 2025, to capture her reaction to being named a recipient of the Nobel Prize in Physiology or Medicine. This story publishes a series of photos that depict Brunkow’s surprise and emotion.

GeekWire traces ISB’s Mary Brunkow’s Nobel-winning FOXP3 discovery back to Darwin Molecular, a scrappy Seattle biotech backed by Microsoft co-founders Bill Gates and Paul Allen. Brunkow recounts the team science that pinpointed FOXP3 and the local celebration at ISB as her work reshapes immunology.

The Seattle Times profiles ISB’s Mary Brunkow – newly named 2025 Nobel laureate – through a very Seattle awakening: she muted predawn calls from Sweden, then believed only when a photographer arrived at her door. The story pairs that moment with her FOXP3/Treg discovery that reshaped immune tolerance.

Reuters highlights ISB’s Mary Brunkow as co-winner of the 2025 Nobel in Physiology or Medicine, spotlighting her mouse-genetics discovery of FOXP3 as the hallmark of regulatory T cells and peripheral immune tolerance – work now powering Treg-based trials and new therapies for autoimmunity, transplantation, and cancer.

A story that maps the road from puzzling autoimmunity to the immune system’s “brakes” – regulatory T cells and FOXP3 – and the moment those clues crystallize into a Nobel morning for Mary Brunkow and collaborators.